The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web editor Nicole Raleigh sat down with Pfizer’s ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

On Jan 15, Pfizer Inc. ( PFE, Financial) announced to sale of about 700 million ordinary shares of Haleon plc through a ...

On the face of it, Pfizer's ROE is not much to talk about. A quick further study shows that the company's ROE doesn't compare ...